Hill, Kyle
`
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Trials <Trials@USPTO.GOV>
`Friday, July 21, 2017 11:34 AM
`Parmelee, Steve; Trials
`Rosato, Michael; Mills, Jad; Devine, Wendy; Phillips, Anna;
`GSpeier@carlsoncaspers.com; 'MSchuman@carlsoncaspers.com';
`mdzwonczyk@sughrue.com; 'tribar@sughrue.com'; 'Azy S. Kokabi
`(akokabi@sughrue.com)' (akokabi@sughrue.com); 'whelan@fr.com'; Michael Kane;
`Jonathan Singer; Susan Morrison
`RE: Conf. Call Request for IPR2016-01127, -01128, -01129, -01130, -01131, and
`-01132
`
`Counsel,
`
`The panel has reviewed Patent Owner’s sur-replies filed in these proceedings, and has determined that additional briefing
`or motion practice is not warranted at this point. Petitioner may address both the substance and the alleged impropriety
`of the sur-replies during oral argument.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`
`
`
`From: Parmelee, Steve [mailto:sparmelee@wsgr.com]
`Sent: Wednesday, July 19, 2017 8:49 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: Rosato, Michael <mrosato@wsgr.com>; Parmelee, Steve <sparmelee@wsgr.com>; Mills, Jad <jmills@wsgr.com>;
`Devine, Wendy <wdevine@wsgr.com>; Phillips, Anna <anphillips@wsgr.com>; GSpeier@carlsoncaspers.com;
`'MSchuman@carlsoncaspers.com' <mschuman@carlsoncaspers.com>; mdzwonczyk@sughrue.com;
`'tribar@sughrue.com' <tribar@sughrue.com>; 'Azy S. Kokabi (akokabi@sughrue.com)' (akokabi@sughrue.com)
`<akokabi@sughrue.com>; 'whelan@fr.com' <Whelan@fr.com>; Michael Kane <kane@fr.com>; Jonathan Singer
`<singer@fr.com>; Susan Morrison <morrison@fr.com>
`Subject: Conf. Call Request for IPR2016-01127, -01128, -01129, -01130, -01131, and -01132
`
`Your Honors,
`
` I
`
` write on behalf of Petitioner Mylan Pharmaceuticals Inc. to request a conference call to discuss Patent Owner’s
`inclusion of new arguments and new evidence in its sur-replies that were filed on July 14, 2017. Because we believe
`they are not responsive to any purported “new issues” in Petitioners’ Replies, we seek the Board’s guidance regarding
`appropriate remedies. Petitioner believes that some combination of (1) an order finding the new exhibits are entitled to
`no weight; (2) authorization to file a motion to strike; and/or (3) authorization to file substantive briefing to address the
`new exhibits and arguments, are justified. Patent Owner has indicated it opposes Petitioner’s request.
`
`Counsel for Petitioner and Patent Owner are available Thursday July 20, after 1pm Eastern; or Friday July 21, after 11am
`Eastern.
`
`1
`
`MYLAN - EXHIBIT 1136
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`

`

`
`Respectfully,
`
`Steven W. Parmelee
`Wilson Sonsini Goodrich & Rosati
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104
`
`206-883-2542 Direct
`sparmelee@wsgr.com | www.wsgr.com
`
`
`
`
`This email and any attachments thereto may contain private, confidential, and privileged material for the sole
`use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by
`others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and
`permanently delete the original and any copies of this email and any attachments thereto.
`
`2
`
`